HC Wainwright & Co. Maintains Buy on Bicara Therapeutics, Lowers Price Target to $36
Benzinga Newsdesk 6 hours ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Robert Burns maintains Bicara Therapeutics (NASDAQ:BCAX) with a Buy and lowers the price target from $42 to $36.
HC Wainwright & Co. analyst Robert Burns maintains Bicara Therapeutics (NASDAQ:BCAX) with a Buy and lowers the price target from $42 to $36.